



Preventing Septic Shock and Death with Peptide Antibodies

[View U.S. Patent No. 9,657,109 in PDF format.](#)

WARF: P120312US01

Inventors: Mark Cook, Jordan Sand, Daniel Butz

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing methods for treating systemic inflammatory response syndromes, including sepsis, by inhibiting the sPLA₂-IB digestion enzyme.

Overview

More than half a million people develop severe sepsis and 215,000 die each year, costing billions of dollars in the United States alone. Sepsis is a type of severe inflammatory response syndrome (SIRS) triggered by a pathogenic microorganism. Animals and humans undergoing intensive (e.g., ventilated) healthcare are particularly vulnerable to infection, which can lead to fatal organ failure.

Current treatments focus on antibiotics, fluid replacement and fever drugs. Yet recent evidence suggests that addressing host inflammation could help prevent sepsis from progressing to shock and death.

The Invention

UW-Madison researchers have identified gastrointestinal tract, e.g., mucosal, inflammation as a key factor in SIRS. From this breakthrough, they have developed oral peptide antibodies to control the inflammation and/or prevent translocation of intestinal luminal bacteria into systemic circulation. The antibodies specifically bind sPLA₂-IB, a pancreatic enzyme traditionally thought to only be involved in the digestion of dietary phospholipids. The antibodies are prepared using standard techniques and may be humanized or avian egg yolk antibodies. They are preferably administered as an oral pharmaceutical.

Applications

- Adjunct treatment for SIRS, including sepsis

Key Benefits

- Targets host inflammation
- Reduces the role of the gastrointestinal tract in driving sepsis progression
- Adds level of protection
- Pharmaceutical can be given easily and safely.

Additional Information

Related Technologies

- [WARF reference number P09241US02 describes liquid crystal devices that could support early diagnosis of sepsis.](#)

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

- [Animals, Agriculture & Food : Animal health](#)
- [Therapeutics & Vaccines : Inflammation](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850

For current licensing status, please contact Emily Bauer at emily@warf.org or 608-960-9842

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850